Paris Abstracts A307 to 0.886 and they all belonged to 5 factors. There was a strong relationship between SCS and EuroQol 5D (r between 0.46-0.76). CONCLUSIONS: The research suggests that the validity and reliability of the Turkish SCS are satisfactory and that it can be used in Turkey. OBJECTIVES: Determine quality of life of COPD patients. METHODS: The medical records of 300 patients with acute exacerbation of COPD who visited City Clinical Hospital #2, with mean age 68.5 4.5 male and 64.8 3.4 female, were retrospectively reviewed. Patients were evaluated on the criteria for COPD [2006]. Sociodemographic data, severity of disease, co-morbidity, and use of health resources in the previous years were collected. SF-36 quality of life questionnaire were administered to all patients. RESULTS: The mean FEV1 value was 45.9 9.1%. The severity of the disease was mild in 139 (46.3%) cases, moderate in 114 (38.0%), severe in 30 (10.0%), very severe in 17 (5.7%). With regard to the use of health resources in the previous year, the mean values were: visits to physician 7,27 1,2 and hospital admissions 8,16 0,31. The mean SF-36 scores for patients with mild COPD in the physical component before and after therapy were 84.5 4.2 and 91.2 5.8 with % value (9.2 1.6); moderate 73.2 3.1 and 77.6 4.6 with % value (6.0 1.5); severe 42.2 1.2 and 45.2 2.6 with % (4.5 1.4); very severe 19.8 2.4 and 23.5 3.8 with % value (4.2 1.4). Similarly, the mean SF-36 scores on mental component of all groups of patients under study, ranging from mild to very severe were 69.60 2.1 and 72.3 3.4 with % value (3.1 2.3); 54.6 2.2 and 56.9 3.7 with % value (4.2 1.5); 38.0 2.3 and 39.6 3.1 with % 3.9 0.8; 28.2 1.1 and 29.1 2.4 with % value (4.2 1.3). CONCLUSIONS: Patients had an increase functional dynamic index ( %) of SF-36 in the physical component, and significant reduction was only seen in mental component of patients with severe and very severe cases.
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PRS45 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 475:
A POPULATION-BASED STUDY Bouza C, Lopez T, Sastre M Carlos III Health Institute, Madrid, Spain OBJECTIVES: Mechanical ventilation for acute respiratory failure is likely to be a Mechanical ventilation for acute respiratory failure is likely to be a reliable indicator of critical care resource requirements on a population level. Our aim is to analyze the costs and discharge status for patients with respiratory failure needing mechanical ventilation (DRG code 475) in Spain and to examine the impact of age in terms of hospital outcome. METHODS: From the 2004 National Hospital Discharge Database all records aged 16 years with a final DRG 475 were retrieved. This DRG, defined as "respiratory system diagnosis with mechanical ventilation", includes three procedure codes and is applied to patients undergoing mechanical ventilation for a variable period of time. Demographic characteristics, clinical outcomes and hospitalresources utilization were examined. An exploratory logistic regression analysis was performed to identify factors associated with in-hospital mortality. To depict the amount of resources spent to procure a given level of desired outcome (hospital survival) we determined the cost per survivor based in the average national charges for DRG 475. RESULTS: 4267 cases were eligible for analysis. Mean age was 64 yr, 71% 4267 cases were eligible for analysis. Mean age was 64 yr, 71% yr, 71% yr, 71% were men and 85% medical patients. According to Charlson index, 45% of cases had no associated comorbidity. Overall 36% of cases required prolonged mechanical ventilation. In-hospital mortality was 39%. Median LOS was 14 days. Total hospital costs were ª 42,581,929. Multivariate logistic regression showed that age significantly correlated with in-hospital mortality after adjusting for comorbidities, principal cause of hospital admission and duration of mechanical ventilation. An inverse relationship between survival rate and age was observed and this resulted in an age-related increased cost per survivor. CONCLUSIONS: Age has a significant impact on out-Age has a significant impact on outcomes in patients under DRG 475. These analyses will help inform health care decision-making and resource planning in the face of an ageing population. This study This study has been supported by the Spanish National I D Program (grant number STPY STPY 1456/07). ).
PRS46
OFF-LABEL PRESCRIBING OF INHALED CORTICOSTEROID/ LONG ACTING BETA-AGONIST COMBINATION PRODUCTS IN COPD PATIENTS
Rigney U, Emmas C, Morais J AstraZeneca UK Ltd, Luton, UK OBJECTIVES: Despite different licences for the use of inhaled corticosteroids/ long acting beta-agonist combination products for Chronic Obstructive Pulmonary Disease (COPD) and asthma, anecdotal evidence suggests general practitioners prescribe similar formulations and doses for both diseases. For patients with COPD, where the licences are more restricted, this may lead to "off-label" prescribing. The objective of this study was to examine the frequency and nature of "off-label" pre-scribing of combination products in COPD patients. METHODS: This was a retrospective cohort study using data from the General Practice Research Database (GPRD), a large nationally representative UK primary care database. All combined salmeterol/fluticasone and formoterol/budesonide prescriptions written between Jan 2006 and Dec 2007 for patients with a Read code for COPD were selected. "Off-label" prescribing was defined as any formulation and/ or dose of salmeterol/ fluticasone or formoterol/budesonide not licensed for COPD. The proportion of "off-label" prescriptions was calculated for each of the 2 treatments and "off-label" prescriptions were further subdivided into whether they were "off-label" with respect to formulation or dose. All calculations were replicated at the patient level and reported in relation to age, sex and smoking status. RESULTS: The analyses were based on a total of 21,137 COPD patients receiving combination products (salmeterol/fluticasone: 17,115; formoterol/budesonide: 4,809) between 2006-2007. 77% of prescriptions were "off-label", 71% for an incorrect formulation and 6% for an incorrect dose. 86% of salmeterol/fluticasone prescriptions were "off-label" (85% formulation, 1% dose) versus 37% of formoterol/budesonide prescriptions (10% formulation, 27% dose). The most frequently prescribed unlicensed formulations were salmeterol 25 mcg/fluticasone 250 mcg pMDI (45%) and salmeterol 25 mcg/ fluticasone 125 mcg pMDI (20%). CONCLUSIONS: "Off-label" prescribing of combination therapy in COPD patients is very common in the UK. The impact of off-label prescribing on efficacy and patient safety is unknown; "off-label" prescribing potentially represents an economically wasteful prescribing practice.
PRS47 SEASONAL VERSUS NEEDS-BASED IMMUNIZATION SCHEDULES-THE EXAMPLE OF RSV
Hampp C, Winterstein AG University of Florida, Gainesville, FL, USA OBJECTIVES: Due to cost reaching $10,000/season, respiratory syncytial virus (RSV) immunoprophylaxis is limited to high-risk periods, but season determination is heavily debated and absolute risk varies significantly by geographic location. We present monthly RSV incidence rates to estimate absolute burden of disease and numbers needed to treat (NNT) to provide an alternative to a dichotomous season definition. METHODS: Medicaid fee-for service recipients 2 years old from California and Florida (1999-2004) were selected if they met high-risk criteria for RSV infections (chronic lung disease or congenital heart disease based on ICD-9 codes, or prematurity up to 32 weeks' gestational age based on birth certificates). Monthly RSV hospitalization rates were broken down by recipients' age and adjusted for the effects of immunoprophylaxis. NNTs were calculated as inverse of the absolute risk reduction (based on relative risk reduction from clinical trial data: 50%). Results in Florida were separated in 5 surveillance regions. RESULTS: California showed a very distinct season from December-March with almost zero viral activity outside. NNTs were smallest in February ( 50) but increased with increasing age. In Florida, no months had zero activity; however, NNTs were never below 125, regardless of age. Among children 1 year, the lowest NNT was 252 [95% CI: 129-5,875] and NNTs exceeded 500 for 8 months (January-August). While the northern regions showed a short, distinct season, the southern regions experienced prolonged activity, most obvious in the southeast. Yet, April through July in the southwest and May/June in the southeast showed NNTs exceeding 650 while the winter months had a peak activity that was comparable to other regions. CONCLUSIONS: NNTs can address differences in burden of disease during the RSV season and between geographic regions and assure equitable access to prophylaxis. Reduced RSV incidence in the second year of life should be incorporated in decisions for immunoprophylaxis.
PRS48 A SURVEY OF TOBACCO CESSATION INTERVENTIONS IN THE DENTAL SETTING IN JAPAN: NICOTINE REPLACEMENT THERAPY, ATTITUDES TOWARDS TOBACCO CESSATION EDUCATION, AND BARRIERS TO CESSATION COUNSELING
Nakao H 1 , Yoshimi I 1 , Fukuda Y 2 , Sata F 1 , Imai H 1 1 National Institute of Public Health, Wako-shi, Saitama, Japan, 2 Yamaguchi University, Ube, Yamaguchi, Japan OBJECTIVES: Tobacco has been identified as a major risk factor for lung cancer, heart disease, and respiratory disease. Adults rarely visit their physicians for preventive care. But surveys have shown that more than half of adult smokers see a dentist each year for preventive care. This may put dentists in a better position to implement tobacco cessation interventions. The aim of the study was to investigate the tobacco cessation interventions conducted by dental practitioners in Japan. METHODS: The study used a survey mailed to dentists (n 1489) in three prefectures (Tokyo, Iwate, Yamanashi) asking about the practitioners' tobacco cessation activities, patient demographic characteristics, barriers to counseling, and attitudes towards tobacco in 2008. RESULTS: The response rate was 57% (n 847). Dentists advised 22% of patients to cease tobacco. More than half of them used a pamphlet or other printed materials. However, nicotine replacement therapy was prescribed infrequently (nicotine patches in 3.2% and nicotine gum in 2.2% of patients). Asked whether dentists should perform tobacco cessation interventions in their offices, 76% said yes. The main barrier to cessation counseling was insufficient time, followed by a lack of knowledge and tobacco cessation specialists to whom to refer patients. 85% of respondents had no education or training in promoting tobacco cessation. Twenty-two percent of all respondents were smokers. CONCLUSIONS: Few dentists perform tobacco cessation interventions in their offices. Nicotine replacement therapy was hardly prescribed at all. Dentists have a positive attitude towards tobacco cessation interventions and
